BPC-157

Mechanism

In rodent and in-vitro models, BPC-157 is reported to promote angiogenesis (new blood-vessel formation) and to upregulate VEGFR2 (vascular endothelial growth factor receptor 2) signalling, with effects linked to the nitric oxide (NO) pathway (Chang et al., 2011; Sikiric et al., 2018). It has also been associated with modulation of growth-factor and FAK-paxillin signalling in tendon fibroblasts in vitro (Chang et al., 2011). These are mechanistic findings from preclinical models; human pharmacokinetics and pharmacodynamics are not established.

Evidence base

Research Summary

The evidence base for BPC-157 is graded limited here because it is overwhelmingly preclinical.

Tendon and ligament healing (animal + in vitro). In a rat Achilles tendon transection model, BPC-157 improved tendon healing and functional recovery (Krivic et al., 2006). In vitro, BPC-157 increased the survival, spreading and migration of cultured tendon fibroblasts and influenced the FAK-paxillin pathway, offering a candidate mechanism (Chang et al., 2011).

Muscle healing (animal). In rat models of crush and transection injury, BPC-157 was reported to accelerate muscle healing and counter the effects of certain agents that impair it (Novinscak et al., 2008).

Gut and gastrointestinal protection (animal). BPC-157 has been studied extensively in rodent models of gastrointestinal injury, where it shows cytoprotective and ulcer-healing effects (Sikiric et al., 2018, review).

Angiogenesis (in vitro + animal). A proposed unifying mechanism is the promotion of angiogenesis via VEGFR2 and the NO system (Chang et al., 2011; Sikiric et al., 2018).

Human evidence. There are no published, peer-reviewed randomised controlled trials of BPC-157 in humans establishing efficacy or safety. Claims of human benefit are therefore unsubstantiated by clinical data, and the favourable safety signals reported are from animal studies only. This evidence gap is the single most important fact for any reader to take away.

Protocols

Commonly Discussed Protocols

The following figures reflect dose ranges and patterns commonly discussed in research and animal-study contexts. They are reported here for completeness and are not medical dosing instructions, nor a recommendation for human use.

• Route: In animal studies, BPC-157 has been administered intraperitoneally, intragastrically (orally) and topically; injectable (subcutaneous) use is the form most discussed in research-community contexts. Notably, oral stability is one reason the gut effects are studied (Sikiric et al., 2018).
• Dose ranges discussed: Research-community discussion commonly references figures in the region of 200-500 micrograms per day; animal study doses are typically expressed per kilogram of body weight and do not translate directly to humans.
• Cycle length discussed: Discussion commonly references short courses (for example, a few weeks) aligned to an injury-recovery window, followed by time off.

Because no human trials exist, there is no validated human dose, schedule or safety margin. Any figure circulating in the community is extrapolated from animal work and should be treated with caution.

UK legal status

BPC-157 is not a licensed medicine in the UK — it has no marketing authorisation from the MHRA (Medicines and Healthcare products Regulatory Agency) for any human use. It is sold and bought as a research chemical "for research use only".

In practice this places BPC-157 in a grey area: it is not a controlled substance under the Misuse of Drugs Act, but selling or supplying it for human consumption — or making medicinal claims about it — would bring it within the scope of the Human Medicines Regulations 2012 and MHRA enforcement. Purchase and possession of research chemicals for genuine research purposes is not in itself illegal, but the product is unlicensed and unregulated for human use.

Note that US-specific framing you may encounter online (FDA categorisation, for example) does not apply in the UK; UK readers should refer to MHRA guidance.

Vendor notes

Vetted UK Vendors

No UK vendors have yet completed Peptide Data's vetting criteria (purity testing, COA availability, shipping and reputation) for inclusion on this profile. Vendor links will be added here once approved vendor pages are published. We do not list vendors that have not met the minimum vetting bar.